Human cytomegalovirus inhibition by cardiac glycosides: Evidence for involvement of the hERG gene

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 9, 2012, Pages 4891-4899

  Kapoor, Arun ^a   Cai, Hongyi ^a   Forman, Michael ^b   He, Ran ^a   Shamay, Meir ^b   Arav Boger, Ravit ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL RECEPTOR; DIGITOXIN; DIGOXIN; GANCICLOVIR; OUABAIN; POTASSIUM CHANNEL HERG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DNA REPLICATION; DOWN REGULATION; DRUG TARGETING; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; MALE; PRIORITY JOURNAL; UPREGULATION; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CARDIAC GLYCOSIDES; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; CYTOMEGALOVIRUS; DIGITOXIN; DIGOXIN; ETHER-A-GO-GO POTASSIUM CHANNELS; FIBROBLASTS; GENE EXPRESSION; GENES, REPORTER; HUMANS; MICE; NF-KAPPA B; OUABAIN; TRANSCRIPTIONAL ACTIVATION; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 84865426387     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00898-12     Document Type: Article

References (54)

1. Arav-Boger R, et al. 2010. Artemisinin-derived dimers have greatly improved anti-cytomegalovirus activity compared to artemisinin monomers. PLoS One 5:e10370. doi:10.1371/journal.pone.0010370.
2. + current highly conserved in tumors of different histogenesis: a selective advantage for cancer cells? Cancer Res. 58:815- 822.
3. Cherrington JM, Mocarski ES. 1989. Human cytomegalovirus ie1 transactivates the alpha promoter-enhancer via an 18-base-pair repeat element. J. Virol. 63:1435-1440. (Pubitemid 19061389)
4. Chou S, et al. 2011. The unique antiviral activity of artesunate is broadly effective against human cytomegaloviruses including therapy-resistant mutants. Antivir. Res. 92:364 -368.
5. Chou SW. 2001. Cytomegalovirus drug resistance and clinical implications. Transpl. Infect. Dis. 3(Suppl 2):20 -24.
6. Demmler GJ. 1991. Infectious Diseases Society of America and Centers for Disease Control: summary of a workshop on surveillance for congenital cytomegalovirus disease. Rev. Infect. Dis. 13:315-329.
7. Dodson AW, Taylor TJ, Knipe DM, Coen DM. 2007. Inhibitors of the sodium potassium ATPase that impair herpes simplex virus replication identified via a chemical screening approach. Virology 366:340 -348.
8. Evers DL, Wang X, Huong SM, Andreoni KA, Huang ES. 2005. Inhibition of human cytomegalovirus signaling and replication by the immunosuppressant FK778. Antivir. Res. 65:1-12. (Pubitemid 40094769)
9. Ficker E, Dennis AT, Wang L, Brown AM. 2003. Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel HERG. Circ. Res. 92:e87- e100.
10. Goldner T, et al. 2011. The novel anti-cytomegalovirus compound AIC246 inhibits HCMV replication through a specific antiviral mechanism that involves the viral terminase. J. Virol. 85:10884 -10893.
11. Griffiths PD, Clark DA, Emery VC. 2000. Betaherpesviruses in transplant recipients. J. Antimicrob. Chemother. 45 (Suppl T3):29 -34.
12. Gupta RS, Chopra A, Stetsko DK. 1986. Cellular basis for the species differences in sensitivity to cardiac glycosides (digitalis). J. Cell Physiol. 127:197-206. (Pubitemid 16074723)
13. Hartley C, Hartley M, Pardoe I, Knight A. 2006. Ionic contra-viral therapy (ICVT); a new approach to the treatment of DNA virus infections. Arch. Virol. 151:2495-2501. (Pubitemid 44819343)
14. Haux J, Klepp O, Spigset O, Tretli S. 2001. Digitoxin medication and cancer: case control and internal dose-response studies. BMC Cancer 1:11. doi:10.1186/1471-2407-1-11.
15. He R, et al. 2011. Recombinant luciferase-expressing human cytomegalovirus (CMV) for evaluation of CMV inhibitors. Virol. J. 8:40.
16. Herrmann EC, Jr, Herrmann JA. 1977. A working hypothesis: virus resistance development as an indicator of specific antiviral activity. Ann. N. Y. Acad. Sci. 284:632- 637.
17. Isomura H, Stinski MF. 2003. The human cytomegalovirus major immediate-early enhancer determines the efficiency of immediate-early gene transcription and viral replication in permissive cells at low multiplicity of infection. J. Virol. 77:3602-3614. (Pubitemid 36297280)
18. Isomura H, et al. 2005. Two Sp1/Sp3 binding sites in the major immediate-early proximal enhancer of human cytomegalovirus have a significant role in viral replication. J. Virol. 79:9597-9607. (Pubitemid 41022303)
19. Jabs DA, Martin BK, Forman MS. 2010. Mortality associated with resistant cytomegalovirus among patients with cytomegalovirus retinitis and AIDS. Ophthalmology 117:128 -132.
20. Jenke M, et al. 2003. C-terminal domains implicated in the functional surface expression of potassium channels. EMBO J. 22:395- 403.
21. Jilek BL, et al. 2012. A quantitative basis for antiretroviral therapy for HIV-1 infection. Nat. Med. 18:446-451.
22. Johnson RA, Huong SM, Huang ES. 2000. Activation of the mitogen-activated protein kinase p38 by human cytomegalovirus infection through two distinct pathways: a novel mechanism for activation of p38. J. Virol. 74:1158 -1167.
23. Johnson RA, Wang X, Ma XL, Huong SM, Huang ES. 2001. Human cytomegalovirus upregulates the phosphatidylinositol 3-kinase (PI3-K) pathway: inhibition of PI3-K activity inhibits viral replication and virus-induced signaling. J. Virol. 75:6022- 6032.
24. Kovacs A, et al. 1999. Cytomegalovirus infection and HIV-1 disease progression in infants born to HIV-1-infected women. N. Engl. J. Med. 341:77- 84.
25. Langenhan JM, Peters NR, Guzei IA, Hoffmann FM, Thorson JS. 2005. Enhancing the anticancer properties of cardiac glycosides by neoglycorandomization. Proc. Natl. Acad. Sci. U. S. A. 102:12305-12310. (Pubitemid 41266354)
26. Lashmit P, Wang S, Li H, Isomura H, Stinski MF. 2009. The CREB site in the proximal enhancer is critical for cooperative interaction with the other transcription factor binding sites to enhance transcription of the major intermediate-early genes in human cytomegalovirus-infected cells. J. Virol. 83:8893- 8904.
27. Li R, et al. 2011. Conserved herpesvirus kinases target the DNA damage response pathway and TIP60 histone acetyltransferase to promote virus replication. Cell Host Microbe 10:390-400.
28. Limaye AP, et al. 2008. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA 300:413- 422.
29. Lopez-Lazaro M, et al. 2005. Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients. J. Nat. Prod. 68:1642-1645. (Pubitemid 41789573)
30. Lurain NS, Chou S. 2010. Antiviral drug resistance of human cytomegalovirus. Clin. Microbiol. Rev. 23:689 -712.
31. Mijatovic T, et al. 2007. Cardiotonic steroids on the road to anti-cancer therapy. Biochim. Biophys. Acta 1776:32-57. (Pubitemid 47334788)
32. Mitchell DA, et al. 2008. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro. Oncol. 10:10 -18.
33. Newman RA, Yang P, Pawlus AD, Block KI. 2008. Cardiac glycosides as novel cancer therapeutic agents. Mol. Interv. 8:36-49. (Pubitemid 351398451)
34. Osawa R, Singh N. 2009. Cytomegalovirus infection in critically ill patients: a systematic review. Crit. Care. 13:R68.
35. Pardo LA, Contreras-Jurado C, Zientkowska M, Alves F, Stuhmer W. 2005. Role of voltage-gated potassium channels in cancer. J. Membr. Biol. 205:115-124. (Pubitemid 41803688)
36. Pillozzi S, et al. 2002. HERG potassium channels are constitutively expressed in primary human acute myeloid leukemias and regulate cell proliferation of normal and leukemic hemopoietic progenitors. Leukemia 16:1791-1798.
37. Prassas I, Diamandis EP. 2008. Novel therapeutic applications of cardiac glycosides. Nat. Rev. Drug Discov. 7:926 -935.
38. Quastel MR, Vogelfanger IJ. 1971. Interspecies differences in the inhibitory effect of ouabain on lymphocyte transformation. Cell. Immunol. 2:504 -507.
39. Raghavendra PB, Sreenivasan Y, Manna SK. 2007. Oleandrin induces apoptosis in human, but not in murine cells: dephosphorylation of Akt, expression of FasL, and alteration of membrane fluidity. Mol. Immunol. 44:2292-2302. (Pubitemid 46097118)
40. Repke K, Est M, Portius HJ. 1965. On the cause of species differences in digitalis sensitivity. Biochem. Pharmacol. 14:1785-1802.
41. Sanchez V, et al. 2004. Cyclin-dependent kinase activity is required at early times for accurate processing and accumulation of the human cytomegalovirus UL122-123 and UL37 immediate-early transcripts and at later times for virus production. J. Virol. 78:11219 -11232.
42. Schoner W, Scheiner-Bobis G. 2007. Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth. Am. J. Physiol. Cell Physiol. 293:C509 -C536.
43. Schreiber A, et al. 2009. Antiviral treatment of cytomegalovirus infection and resistant strains. Expert Opin. Pharmacother. 10:191-209.
44. Shen L, et al. 2008. Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat. Med. 14:762-766. (Pubitemid 351951518)
45. Soroceanu L, Akhavan A, Cobbs CS. 2008. Platelet-derived growth factor-alpha receptor activation is required for human cytomegalovirus infection. Nature 455:391-395.
46. Steininger C. 2007. Novel therapies for cytomegalovirus disease. Recent Pat. Antiinfect. Drug Discov. 2:53-72.
47. Stenkvist B. 1999. Is digitalis a therapy for breast carcinoma? Oncol. Rep. 6:493- 496.
48. Summers BC, Margolis TP, Leib DA. 2001. Herpes simplex virus type 1 corneal infection results in periocular disease by zosteriform spread. J. Virol. 75:5069 -5075.
49. Tanaka Y, et al. 2002. Monitoring cytomegalovirus infection by antigenemia assay and two distinct plasma real-time PCR methods after hematopoietic stem cell transplantation. Bone Marrow Transplant. 30:315-319.
50. Wang L, Wible BA, Wan X, Ficker E. 2007. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking. J. Pharmacol. Exp. Ther. 320:525-534. (Pubitemid 46147930)
51. Williams SL, et al. 2003. In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses. Antimicrob. Agents Chemother. 47:2186 -2192.
52. +-ATPase-mediated signal transduction: from protein interaction to cellular function. Mol. Interv. 3:157-168.
53. Yurochko AD. 2008. Human cytomegalovirus modulation of signal transduction. Curr. Top. Microbiol. Immunol. 325:205-220.
54. Yurochko AD, et al. 1997. The human cytomegalovirus UL55 (gB) and UL75 (gH) glycoprotein ligands initiate the rapid activation of Sp1 and NF-κB during infection. J. Virol. 71:5051-5059. (Pubitemid 27258175)